Is the Proof of an Additional Benefit Under Amnog in Germany More Difficult for Certain Drugs Than for Other Ones?

Value in Health - United Kingdom
doi 10.1016/j.jval.2015.09.1607
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Relationship Between the Price Differences in Orphan Drugs With More Than One Benefit Assessment in Amnog and the Potential Influencing Factors

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Php35 - Amnog Early Benefit Assessment (Eba) and Market Penetration of New Drugs for Melanoma, Multiple Sclerosis and Diabetes Mellitus in Germany

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Is the Diversification Benefit for Teams More Sustainable Than at the Financial Market?

Wirtschaftsinformatik
Information Systems
2010English

2.5 Years of Amnog in Germany – An Analysis of Benefit Assessment and Net Price Negotiation Trends

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Is the Dalkon Shield More Dangerous Than Other IUCDs?

BMJ
1985English

Predicting Post-Amnog Rebate Outcomes for Oncology Drugs

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Radical Stress Is More Cytotoxic in the Nucleus Than in Other Organelles

International Journal of Molecular Sciences
Organic ChemistryMolecular BiologyTheoretical ChemistryInorganic ChemistryComputer Science ApplicationsSpectroscopyMedicineCatalysisPhysical
2019English

Points: Is the Dalkon Shield More Dangerous Than Other IUCDs?

BMJ
1985English

Editorial: Better Outcomes for Crohn's Disease-More Than Just the Drugs?

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy